demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID-19 mild to moderate
Kinase inhibitors
imatinib Covid-19 HUF

1 studies excluded by filtering options 3

6323 Roschewski, 2020 2990excludednot a RCTrisk of bias not avaialble